Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Scott A. Trapp who wrote (878)	7/24/1998 9:18:00 AM
From: Argonaut	Read Replies (2) \| Respond to of 119973

VISX, should be a mover today. FDA recommended approval of its laser system: VISX First to Receive FDA Panel Approval for Treatment of Farsightedness Business Wire - July 23, 1998 18:42 SANTA CLARA, Calif.--(BW HealthWire)--July 23, 1998--VISX, Inc. (NASDAQ/NMS:VISX) announced today that the FDA Ophthalmic Devices Advisory Panel has recommended approval of its VISX Excimer Laser Systems for use in the treatment of from one to six diopters of hyperopia, or farsightedness. In making its determination, the panel reviewed data from eight U.S. clinical sites. Commenting on the panel's recommendation, Mark Logan, chairman, president and CEO of VISX, stated, "This recommendation is good news and further demonstrates the tremendous technical advantage inherent in our system. The VISX STAR(TM) is capable of correcting myopia, astigmatism and hyperopia without the need for additional devices such as trackers and discs; I believe this is another major benefit for our customers. VISX will be working with the FDA to gain final approval for hyperopia as soon as possible." Dr. James J. Salz, clinical professor of ophthalmology, University of Southern California, and principal VISX investigator at Cedar Sinai Medical Center in Los Angeles, said, "I have been performing hyperopic laser vision correction with the VISX STAR laser system as part of this FDA clinical trial. "The clinical results are outstanding and hyperopic laser vision correction has become my favorite refractive surgical procedure, primarily because of the high level of satisfaction reported by these patients. I am extremely hopeful that FDA approval will soon make this exciting procedure available to all VISX users." Except for historical information, statements relating to the company's plans, objectives and future performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations. Because of various risks and uncertainties, actual strategies and results in future periods may differ materially from those currently expected. Additional discussion of factors affecting the company's business is contained in the company's most recent filings with the Securities and Exchange Commission. VISX is the worldwide leader in the development of refractive laser technology. VISX systems are commercially available in the United States and markets worldwide. CONTACT: VISX Lola Wood, 408/733-2020 Jeffrey Volk, 212/843-8086 ir@visx.com visx.com